<DOC>
	<DOCNO>NCT00168805</DOCNO>
	<brief_summary>A phase III , randomise , parallel-group , double-blind , active control study investigate ef ficacy safety two different dose regimen orally administer dabigatran etexilate capsule [ 150 220 mg daily start half dose ( i.e.75 110 mg ) day surgery ] comp ared subcutaneous enoxaparin 40 mg daily 6 10 day , prevention venous thromboem bolism patient primary elective total knee replacement surgery . RE-MODEL ( Thromboembolism prevention knee surgery )</brief_summary>
	<brief_title>RE-MODEL Dabigatran Etexilate 150mg 220mg Once Daily ( o.d . ) Versus ( v.s . ) Enoxaparin 40mg o.d . Prevention Thrombosis After Knee Surgery</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion Inclusion criterion ( select ) : Patients ( 18 year old ) schedule undergo primary , unilateral , elect ive total knee replacement Written Informed Consent Exclusion criterion Exclusion criterion ( select ) : Patients excessive risk bleeding , example history bleed diathesis major surgery trauma within last 3 month history haemorrhagic stroke follow intracranial pathology : bleeding , neoplasm , arteriovenous ( AV ) malformation aneurysm clinically relevant bleed gastric / duodenal ulcer within last 6 month treatment anticoagulant within 7 day prior joint replacement surgery anticipate need study treatment period thrombocytopenia . Active malignant disease current cytostatic treatment Known severe renal insufficiency Liver disease expect potential impact survival , elevate aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) &gt; 2x upper limit normal Recent unstable cardiovascular disease history myocardial infarction within last 3 month Premenopausal woman pregnant nursing , childbearing pote ntial practising plan continue practise acceptable thods birth control Allergy radio opaque contrast medium iodine , heparin ( incl . heparin indu ced thrombocytopenia ) dabigatran Contraindications enoxaparin Participation clinical trial last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>